MTOR and cancer: Among these pathways, the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is particularly critical, as its dysregulation is frequently linked to tumor progression, resistance to therapy, and poor outcomes across multiple cancer types (2–4).